Altogether, compounds targeting negative regulators of the ERK cascade, such as DUSP6 and SPRY proteins, might offer a treatment strategy for certain cancers by inducing the toxic effects of RAS-mediated hyperactive ERK signaling. The gene discussed is DUSP6; the disease is cancer.